Skip to main content
All lobbying filings

THE MCMANUS GROUP

Lobbying for ROCHE DIAGNOSTICS · Diagnostic test manufacturing

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · Indiana · House · Senate · $40,000.00 income · posted Apr 20, 2026

Official filing document

 Bills named in this filing 3
  • HR 5269
    RESULTS Act
  • HR 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
 Lobbying activity 2
Medicare/Medicaid

H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Trade (domestic/foreign)

Issues related to global trade and tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem